Guobang Pharma (SH:605507) KAIYUAN SECURITIES·2026-03-31 05:46Investment Rating - The investment rating for Guobang Pharmaceutical is "Buy" (maintained) [1] Core Views - The company is expected to achieve steady revenue growth in 2025, with projected revenue of 6.011 billion yuan, a year-on-year increase of 2.05%. The net profit attributable to shareholders is forecasted to be 821 million yuan, up 5.02% year-on-year [5] - The animal health segment is anticipated to reach a price turning point, with a significant increase in sales volume for key products such as Florfenicol and Doxycycline [5][6] - The company has adjusted its profit forecasts for 2026-2027, now estimating net profits of 1.060 billion yuan and 1.291 billion yuan respectively, while introducing a new forecast for 2028 with a net profit of 1.467 billion yuan [5] Financial Performance - In 2025, the company achieved a gross margin of 26.03%, an increase of 1.03 percentage points, and a net margin of 13.6%, up 0.35 percentage points [5] - The revenue from the animal health segment was 2.492 billion yuan, reflecting a year-on-year growth of 15.35%, while the pharmaceutical segment saw a decline of 9.08% to 3.475 billion yuan [6] - The company has a high valuation attractiveness with a current price-to-earnings ratio (P/E) of 14.2 for 2026, 11.6 for 2027, and 10.2 for 2028 [5][9] Business Structure and Product Development - The company has optimized its business structure, with over 80 products in production and sales, including 13 products generating over 100 million yuan in revenue [6] - Significant progress in product registration has been made, with several key products receiving international certifications, enhancing the company's competitive position [7] Research and Development - The company maintains a high level of research and development intensity, with a research expense ratio of 3.49% in 2025 [7]